Empowered Patient Podcast

Dan Passeri, CEO, Cue Biopharma discusses their proprietary Immuno-STAT(TM) platform. Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The platform is designed to harness the body's intrinsic immune system response without the need for ex vivo manipulation. Cue is currently conducting a Phase 1 study in HPV16-driven head and neck cancer and partnering with Merck to develop treatments for autoimmune diseases.

#immunooncology #HNSCC. #TCells

@CueBiopharma

CueBiopharma.com

Listen to the podcast here.

Download the entire transcript from this episode page

TRANSCRIPT Page 1:

Karen Jagoda:

Welcome to the empoweredpatientpodcast.com show. I'm Karen Jagoda, and my guest today is Dan Passeri. He's the CEO of Cue Biopharma. That's cuebiopharma.com. And I recently talked with Anish Suri, who is the Chief Scientific Officer at Cue, and I thought it was such an interesting story that I thought it was also a good idea to get the CEO of the company on the show to give us a little bit of an update and perhaps a little bit more in the way of details. So welcome to the show today, Dan.

Dan Passeri:

Thanks, Karen. Appreciate it.

Karen Jagoda:

So let's just talk a little bit about where Cue fits into the landscape of immuno-oncology companies.

Dan Passeri:

Sure. Immuno-oncology is obviously a very broad, encompassing category, and what it really covers is any approach that is meant to stimulate the immune system in some manner, that is meant to have clinical activity against cancer. And there's a myriad of approaches, but ultimately, no matter what approach is being taken, the objective is to stimulate the effective components of the immune system that can identify and attack cancer.

Dan Passeri:

What we do is actually quite distinctive in that the majority of approaches have tried to stimulate T-cells in various ways by taking them out of the body, for instance. And we've all heard of all these various cell therapy approaches, CAR T being the best publicized and characterized. And that's where you're taking T-cells out of the patient, you're genetically altering them to have a particular receptor that recognizes cancer, and infusing them back in.

Dan Passeri:

There are also cell therapy approaches where they take the cells out and use particular proteins that are represented on cancer, and then those T-cells will recognize that protein, and they use something called IL-2, Interleukin-2. It's an approved drug called proleukin, and they'll stimulate the T-cells, and then they infuse them back into the body.

Dan Passeri:

What we're doing is quite a different approach, and we believe it's a transformative approach in that we are using a biologic engineering category to stimulate T-cells directly in the patient's body. So it basically removes the need for having to extract T-cells out of the patient and the cumbersome manipulations, and we believe what we'll have is a potential breakthrough in the space where we can use our biologic to engage the desired T-cells. Now, that is only those T-cells that will recognize the protein on the cancer, activate those T-cells, and make many copies of them so that they then will identify the tumor cells, attack them, and destroy them. So that's the broad overview of what we're doing.

Karen Jagoda:

So when I heard you describe what you're up to, it sounded like there were lots of advantages. One, a time factor. You don't have to take the cells out and put them back in the body after a certain period of time. But also it sounds like you might be able to reduce the unintended consequences or the side effects. Can you say a little bit about what goes on when you approach the cancer in this way?

Download the entire transcript.

Sponsored by

Dan Passeri, CEO, Cue Biopharma discusses their proprietary Immuno-STAT(TM) platform. Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The platform is designed to harness the body's intrinsic immune system response without the need for ex vivo manipulation. Cue is currently conducting a Phase 1 study in HPV16-driven head and neck cancer and partnering with Merck to develop treatments for autoimmune diseases.

#immunooncology #HNSCC #TCells

@CueBiopharma

CueBiopharma.com

Download the entire transcript here

Page 1 of Transcript

Karen Jagoda:

Welcome to the empoweredpatientpodcast.com show. I'm Karen Jagoda, and my guest today is Dan Passeri. He's the CEO of Cue Biopharma. That's cuebiopharma.com. And I recently talked with Anish Suri, who is the Chief Scientific Officer at Cue, and I thought it was such an interesting story that I thought it was also a good idea to get the CEO of the company on the show to give us a little bit of an update and perhaps a little bit more in the way of details. So welcome to the show today, Dan.

Dan Passeri:

Thanks, Karen. Appreciate it.

Karen Jagoda:

So let's just talk a little bit about where Cue fits into the landscape of immuno-oncology companies.

Dan Passeri:

Sure. Immuno-oncology is obviously a very broad, encompassing category, and what it really covers is any approach that is meant to stimulate the immune system in some manner, that is meant to have clinical activity against cancer. And there's a myriad of approaches, but ultimately, no matter what approach is being taken, the objective is to stimulate the effective components of the immune system that can identify and attack cancer.

Dan Passeri:

What we do is actually quite distinctive in that the majority of approaches have tried to stimulate T-cells in various ways by taking them out of the body, for instance. And we've all heard of all these various cell therapy approaches, CAR T being the best publicized and characterized. And that's where you're taking T-cells out of the patient, you're genetically altering them to have a particular receptor that recognizes cancer, and infusing them back in.

Dan Passeri:

There are also cell therapy approaches where they take the cells out and use particular proteins that are represented on cancer, and then those T-cells will recognize that protein, and they use something called IL-2, Interleukin-2. It's an approved drug called proleukin, and they'll stimulate the T-cells, and then they infuse them back into the body.

Dan Passeri:

What we're doing is quite a different approach, and we believe it's a transformative approach in that we are using a biologic engineering category to stimulate T-cells directly in the patient's body. So it basically removes the need for having to extract T-cells out of the patient and the cumbersome manipulations, and we believe what we'll have is a potential breakthrough in the space where we can use our biologic to engage the desired T-cells. Now, that is only those T-cells that will recognize the protein on the cancer, activate those T-cells, and make many copies of them so that they then will identify the tumor cells, attack them, and destroy them. So that's the broad overview of what we're doing.

Dr. Arnold Saperstein, Chief Medical Officer, Cecelia Health talks about how they are empowering diabetics to manage their disease as well as overall healthcare using personalized human to human coaching based on an individual's background, age and specific needs. Their mission is to address challenges of medication compliance, insuring patients understand the role of diet and nutrition, and working with patients to remove barriers to the effective use of technology to help control their conditions.

@CeceliaHealth

#diabetes #mobilehealth

CeceliaHealth.com

Listen to the podcast here

Sponsored by

Dr. Arnold Saperstein, Chief Medical Officer, Cecelia Health talks about how they are empowering diabetics to manage their disease as well as overall healthcare using personalized human to human coaching based on an individual's background, age and specific needs. Their mission is to address challenges of medication compliance, insuring patients understand the role of diet and nutrition, and working with patients to remove barriers to the effective use of technology to help control their conditions.

@CeceliaHealth

#diabetes #mobilehealth

CeceliaHealth.com

Download the transcript here

Kinnari Patel, Chief Operating Officer, Rocket Pharmaceuticals discusses how Rocket is focused on creating new options for patients contending with rare genetic diseases. Rocket is advancing several gene therapies for rare pediatric diseases and Kinnari provides insights into how the company is tackling the unique challenges facing patients with rare diseases, their caregivers and the community at large. This February 29th Rocket Pharma is hosting a Rare Disease Day event featuring patient discussions and opportunities for patients and families to engage with physicians and researchers in the NY healthcare community.

@RocketPharma

#RareDiseaseDay #RareDiseases #GeneticDisease #GeneTherapy #FanconiAnemia #DanonDisease #PatientFocused

RocketPharma.com

Listen to the podcast here

Sponsored By

TREND.Community

Kinnari Patel, Chief Operating Officer, Rocket Pharmaceuticals discusses how Rocket is focused on creating new options for patients contending with rare genetic diseases. Rocket is advancing several gene therapies for rare pediatric diseases and Kinnari provides insights into how the company is tackling the unique challenges facing patients with rare diseases, their caregivers and the community at large. This February 29th Rocket Pharma is hosting a Rare Disease Day event featuring patient discussions and opportunities for patients and families to engage with physicians and researchers in the NY healthcare community.

@RocketPharma

#RareDiseaseDay #RareDiseases #GeneticDisease #GeneTherapy #FanconiAnemia #DanonDisease #PatientFocused

RocketPharma.com

Download the transcript here

Renee Ryan, CEO, Cala Health talks about the focus of Cala on using electricity as medicine by developing wearable electronics to treat tremors in the hands of essential tremor patients. Using neuromodulation technology, they have developed a device that includes a stimulator and a signal that is sent across two nerves in the wrist to read the frequency of the tremors and allow the patient to reduce tremors on demand.

@calahealth

#mobilehealth #essentialtremors #neuromodulation

Cala Health

Listen to the podcast here

Sponsored by

Renee Ryan, CEO, Cala Health talks about the focus of Cala on using electricity as medicine by developing wearable electronics to treat tremors in the hands of essential tremor patients. Using neuromodulation technology, they have developed a device that includes a stimulator and a signal that is sent across two nerves in the wrist to read the frequency of the tremors and allow the patient to reduce tremors on demand.

@calahealth

#mobilehealth #essentialtremors #neuromodulation

Cala Health

Download the transcript here

James Brown DVM, CEO, DURECT Corporation talks about how DURECT is advancing epigenetic therapies to treat alcoholic hepatitis and non-alcoholic steatohepatitis (NASH). The company's lead asset, DUR-928 has demonstrated promising therapeutic potential treating patients with alcoholic hepatitis, a life-threatening acute liver disease caused by chronic alcohol abuse with no approved drugs for treatment. Dr. Brown also talks about his background as a doctor of veterinary medicine and his goal to continue developing medicines that improve the lives of others.

#AlcoholicHepatits #Epigenetic #NASH #LiverDisease

DURECT.com

Listen to the podcast here

Sponsored by

James Brown DVM, CEO, DURECT Corporation talks about how DURECT is advancing epigenetic therapies to treat alcoholic hepatitis and non-alcoholic steatohepatitis (NASH). The company's lead asset, DUR-928 has demonstrated promising therapeutic potential treating patients with alcoholic hepatitis, a life-threatening acute liver disease caused by chronic alcohol abuse with no approved drugs for treatment. Dr. Brown also talks about his background as a doctor of veterinary medicine and his goal to continue developing medicines that improve the lives of others.

#AlcoholicHepatits #Epigenetic #NASH #LiverDisease

DURECT.com

Download the transcript here